Sebastian Kreiter to Present on Pioneering Developments in RNA Immunology at Cancer Vaccines 2015

Share Article

Author and leading scientist Dr Sebastian Kreiter from BioNtech RNA talks to SMi Group about the latest developments in RNA vaccinology and his upcoming presentation in an exclusive new interview.

Cancer Vaccines 2015

Cancer Vaccines 2015

"I will present first results from our early clinical trials (MERIT, warehouse)" - Dr Sebastian Kreiter

SMi Group’s 4th annual Cancer Vaccines conference will lay out an agenda aimed to empower researchers with the knowledge to develop the next generation of cancer therapeutics. A presentation by the VP of Immunotherapy at BioNTech RNA, Dr Sebastian Kreiter, will be just one of the highlights at the show taking place in London this autumn.

Dr Kreiter recently took part in the pioneering development of actively personalized cancer vaccination where he worked out the scientific and technical PoC for an mRNA based mutanome vaccine in murine model systems together with team members.

His presentation entitled: RNA - Vaccinology: From Ware-Houses to Actively Personalized Cancer Vaccines will discuss simulating tumour-specific antigen recognition with a focus on epitope design of multi-antigen tumour vaccines and neo-antigens.

When asked who how accessible fully - personalised cancer treatments would become, he said:

“We use an individually tailored synthetic RNA vaccine for inducing immune responses against multiple mutations thereby enabling the patient’s immune system to specifically recognize and attack the cancer cells (“MERIT”: Mutanome Engineered RNA Immuno-Therapy). Conceptually this therapy is suitable for all cancer indications and we are aiming to develop it as universal “just in time” medicine. Our objective is to make our approach of truly personalized cancer immunotherapies available for a broad range of patients and at an affordable rate.”

On what attendees will take away from his talk, he commented:

"I will give insight into the main accomplishments of our mRNA vaccine platform demonstrated in pre-clinical studies showing its great potential as cancer vaccine. Furthermore I will present the concept of MERIT ( Mutanome Engineered RNA Immuno-Therapy) and show the preclinical PoC work. Finally I will present first results from our early clinical trials (MERIT, warehouse)."

The full interview is available to read in the conference download centre.

Other key speakers at Cancer Vaccines 2015 will include Kings College London, Vaccinogen, GSK, Roche and the National Cancer Institute.

For further information or to download a brochure visit

Cancer Vaccines 2015
16 - 17 Sept 2015
Marriott Regents Park, London, UK
Lead sponsor: Northwest Biotherapeutics


About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Teri Arri
SMi Group Ltd
+44 207 827 6162
Email >
since: 10/2011
Follow >